Introduction
Integrated management of childhood illness (IMCI) is a set of standardized clinical algorithms used for the diagnosis and management of common illnesses affecting children in settings with limited access to laboratory diagnostics [1] . A validation study for identifying pediatric HIV-1 infection using a clinical algorithm was first reported in 2003 [2] . In 2006 and 2008, the WHO reported an updated IMCI algorithm for identification of HIV-1 infection based on the presence of two or more of seven clinical criteria [3, 4] . IMCI could potentially be a valuable tool to identify HIV-infected infants in settings in which virologic testing of all exposed infants is unfeasible. Early diagnosis of HIV-1 infection and initiation of antiretroviral therapy (ART) is critical in children under 2 years of age; in the absence of ART infant mortality rates have reached 55% in some African cohorts [5, 6] . In contrast, empiric start of ART at 10 weeks of age reduced mortality risk by 76% in the Children with HIV Early Antiretroviral Therapy (CHER) study [7] . WHO guidelines currently recommend initiation of ART at the time of diagnosis for children less than 2 years of age [8] . Screening for HIV-1 in infants whose mothers access prevention of mother-tochild HIV-1 transmission services should ideally begin at birth, and continue periodically until at least 6 weeks after weaning [9] .
Sensitivity and specificity estimates of HIV-1 clinical algorithms have ranged from 9 to 89% and 42 to 99%, respectively [2, 8, [10] [11] [12] [13] [14] [15] [16] . This wide range of values may be attributed to factors such as age distribution, health status, HIV-1 prevalence, health worker training, and selection of gold standard diagnostic test [8] . Longitudinal studies of IMCI performance are timely in light of these highly discordant results, and the pending 2012 review of evidence proposed by WHO for reevaluation of clinical algorithms among highly vulnerable infant populations [8] . In this report, we utilize a well characterized longitudinal cohort to describe the effect of age on IMCI performance in Kenyan infants during the first year of life, and we estimate the delay in HIV-1 diagnosis when using IMCI compared to virologic testing.
Methods

Study population
Five hundred and ten pregnant, HIV-1-seropositive women were recruited from Nairobi City Council Maternal-Child Health Clinics between July 1999 and November 2002 for a prospective cohort study investigating HIV-1 transmission and infant immunity; details of the cohort and primary analyses are presented elsewhere [6, 17, 18] . Maternal inclusion enrollment criteria included gestation of 32 weeks or less, HIV-1 seropositive, at least 18 years of age, plans to reside in Nairobi for at least a year postpartum, and consent for collection of serial infant blood samples. Women were excluded if study clinicians determined they were too sick to participate. This secondary analysis included infants surviving to at least 1 month of age, who had a minimum of one virologic test and clinical assessment. We excluded infants with loss to follow-up before 1 month of age and second born twins.
Infant HIV-1 virologic diagnosis
Study participants were provided with nutritional counseling and elected either breastfeeding or replacement feeding according to personal preference. This study was conducted before ART became freely available in Kenya; women were provided with short-course zidovudine [19] from 36 weeks gestation according to contemporaneous Kenyan Guidelines, but otherwise received no ART postpartum. Infants received virologic HIV-1 testing within 48 h of birth, 1 month, and then at 3, 6, 9, and 12 months of age. At each of these time points, dried blood was collected onto filter paper and used for HIV-1-gag PCR as previously described [20] . At each time point, HIV-1 viral RNA loads were also measured from cryopreserved plasma specimens using the Gen-Probe assay (Gen-Probe, San Diego, California, USA) [21] . Infants were considered infected on the first of two consecutive positive tests for HIV-1 RNA and/or DNA. The time to HIV-1 infection based on virologic testing was calculated as the midpoint between the last negative and first positive test.
Clinical data collection
The data collection methodology has previously been described [17, [22] [23] [24] . At each monthly visit, a questionnaire was completed with information regarding nutrition, breastfeeding, and intercurrent illness. Physical examinations were conducted by a study pediatrician to assess growth and record clinical findings.
Integrated management of childhood illness clinical diagnostic criteria
As all women were confirmed as HIV-1-seropositive at study enrolment, all infants had known exposure to HIV-1 and did not receive HIV-1 serologic testing. The prospective cohort study did not collect data for the purpose of evaluating IMCI; however, variables assessed were appropriate for a retrospective evaluation of WHO IMCI criteria [3]: persistent diarrhea, very low weight for age, oral thrush, parotitis, lymphadenopathy, pneumonia, and ear discharge. The WHO criteria were modified to include a diagnosis of otitis media or externa as a surrogate for ear discharge. Weight for age z-scores were calculated using WHO Anthro software (WHO, Geneva, Switzerland) [25] . IMCI criteria were evaluated discretely at each study visit; infants were identified as having suspected HIV-1 infection if they met two or more clinical criteria at an individual study visit.
Statistical analysis
All statistical analyses were performed using STATA version 11.0 (StataCorp, College Station, Texas, USA). All tests were two-sided with a value of 0.05. Virologic confirmation of HIV-1 infection was considered the gold standard; IMCI sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated overall (an infant classified at any visit as infected using IMCI criteria) and at each month of age up to 12 months. Fisher's exact test was used to compare frequencies of clinical diagnoses between HIV-infected and HIV-exposed uninfected infants. A cutoff of two clinical criteria was used to compare sensitivity/specificity between age groups (using each infant's maximum IMCI score). Linear regression was used to test for associations between infant age and sensitivity, specificity, PPV, and NPV. For the 86 HIV-infected infants, an incidence rate ratio (IRR) was calculated using a generalized estimating equation regression model with a Poisson link to compare time to HIV-1 diagnosis using virologic testing versus ICMI; an exchangeable working correlation structure with robust standard error was used in this model to account for the correlation between multiple observations per infant. Kaplan-Meier survival analysis and the log-rank test for equality were used to estimate and compare the median time to HIV-1 diagnosis using virologic testing versus IMCI.
Results
Cohort characteristics and follow-up
Of the 476 infants delivered, 468 were live, singleton births. Fourteen infants died before 1 month and 10 were lost to follow-up with no visits at or after the first month of age. The 444 infants with at least one follow-up visit between 1 and 12 months of age were included in this analysis. During the first year of life, infants and their mothers received a median of 11 study visits [interquartile range (IQR) [8] [9] [10] [11] [12] . Seventy-six percent (336 of 444) of mothers breastfed for a median duration of 9 months (IQR 4-12).
Eighty-six infants (19%) were diagnosed with HIV-1 infection during the first year of life using virologic testing (Table 1) . Twenty-eight (33%) infants were diagnosed at their neonatal visit, 42 (49%) infants by month 1, seven (8%) infants at month 3, and the remaining nine (10%) infants were diagnosed after month 3. A total of 30 of 86 (35%) HIV-infected infants and 20 of 358 (5.6%) HIV-exposed uninfected infants in this analysis died between 1 and 12 months. The median age at death was 5.4 months (IQR 4.3-6.9) in HIV-1infected infants and 3.7 months (IQR 2.5-5.0) in HIVexposed uninfected infants. Thirty-six (42%) of the infected infants were never identified using IMCI, 14 (39%) died and five (14%) were lost to follow-up before 12 months of age. All but one of the 14 deaths were among infants with early acquisition (<1 month) of infection.
Frequency of integrated management of childhood illness clinical criteria detected in HIV-infected and HIV-uninfected infants
Clinical criteria were assessed monthly. Except for parotitis, all indicator conditions were commonly reported, with oral thrush (67%), lymphadenopathy (55%), and pneumonia (55%) being the most commonly identified in HIV-1-infected infants ( Table 2) . Oral thrush, lymphadenopathy, persistent diarrhea, pneumonia, and very low weight for age were more frequent in HIV-infected infants compared with uninfected infants (P < 0.0001 for each).
Sensitivity, specificity, and predictive power of integrated management of childhood illness for infant HIV-1 diagnosis Of the 444 infants, 86 (19%) were diagnosed with HIV-1 infection by virologic testing and 97 (22%) were identified as having suspected HIV-1 infection using IMCI (Table 3) IMCI performance was assessed at discrete monthly study visits during the first year of life (Table 3) . At 1 month of age, when 70 infants had already acquired HIV-1 (81% of infections), IMCI correctly identified only one of the HIV-infected infants (sensitivity 1.4%, 1 of 70). Sensitivity was low throughout follow-up, but increased significantly with infant age (Pearson's r 2 ¼ 0.79, P < 0.0001). Specificity remained high (range 97-100%) at each time point and was not associated with infant age (r 2 ¼ 0.06, P ¼ 0.58). The PPV ranged from 14 to 79%, and increased significantly with age (r 2 ¼ 0.33, P ¼ 0.05). PPV was lowest at 1 month of age; only 14% of infants who met IMCI criteria were actually HIVinfected, suggesting IMCI would be a poor tool for screening HIV-1-exposed infants at this critical time point. The NPV ranged from 84 to 91% and was also significantly associated with infant age (r 2 ¼ 0.85, P < 0.0001).
Delay in infant HIV-1 diagnosis using integrated management of childhood illness clinical criteria versus virologic testing
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identified as having suspected HIV-1 infection by IMCI.
Overall, the median time to HIV-1 diagnosis using IMCI was 7.5 months with a median delay of 5.9 months (P < 0.0001). At 6 and 12 months, the probability of undetected true HIV-1 infections when using IMCI was 62 (95% CI 0.49-0.72) and 28% (95% CI 0.18-0.39), respectively.
Among HIV-infected infants, we also compared the median time to diagnosis in infants grouped by timing of HIV-1 acquisition; virologic diagnosis of HIV-1 before 1 month of age was considered 'early' acquisition (70 of 86, 81% of infections, Fig. 1b ) and virologic diagnosis of HIV-1 after 1 month of age was considered 'late breast milk' acquisition (16 of 86, 19% of infections, Fig. 1c ). Of the infants with early HIV-1 acquisition, 60% (42 of 70) eventually met IMCI criteria; the median time to diagnosis using IMCI was 6.6 months of age, with a median delay of 6.1 months (P < 0.0001). Among infants with late HIV-1 acquisition, 50% (eight of 16) eventually met IMCI criteria; the median time to diagnosis using IMCI was 10.5 months, with a median delay of 4.5 months (P < 0.0001).
Discussion
In 2010, the WHO reported a low quality of evidence yet a strong recommendation for use of clinical algorithms and serologic testing in the absence of virologic testing [8] . Healthcare workers in low-resource settings may rely on IMCI to inform decisions about referral for further HIV-1 testing, early ART initiation, cotrimoxazole prophylaxis, and infant feeding. In this longitudinal study comparing IMCI to HIV viral assays, we found that IMCI performance was very low during infancy, but increased with age. Although many truly infected infants were eventually identified using IMCI, reliance on IMCI alone would delay identification of the HIV-infected infant for more than 5 months, an unacceptable delay for infants who are at high risk for opportunistic infections and death in the absence of ART. Our findings support the current push to expand virologic assays for early detection of infant HIVand to foster improved systems to provide these assays to infants.
In this study, IMCI sensitivity increased with age, whereas specificity remained high throughout infancy. Our observation of increasing sensitivity with age is consistent with previous studies [11, 16] , and reflects the increasing incidence of opportunistic infections as HIV-infected infants become immunosuppressed. IMCI performance was poorest at 1 to 2 months of age, when identification of infected infants would be most effective for decreasing morbidity and mortality; this is a time when most transmissions (>80%) have already occurred and is the optimal time frame for HAART initiation, and also the time when infants are most likely to visit health clinics (for routine immunizations at 6 and 10 weeks). Although IMCI sensitivity improves with age, this is offset by deaths in infected children, which results in a lower prevalence of HIV-1 in the population. For example, most children attend the 9-month measles vaccination visit, but at this time point, 31% of HIV-infected children have already died (data not shown), and IMCI sensitivity is only 20% (Table 3) . PPV was also lowest at 1 month of age in this cohort, and remained less than 80% throughout all time points. This is of particular concern for settings in which IMCI is not used as a screening tool, but is rather employed as a diagnostic test, and may be used to guide initiation of ART. In our cohort of children known to be HIV exposed, the prevalence of HIV was high, but in populations in which maternal HIV status may not be known, PPV may be even lower, meaning a substantial number of children could be misdiagnosed and inappropriately started on ART.
To our knowledge, the delay in HIV-1 diagnosis when using IMCI has not been described previously. According to the most recent WHO IMCI algorithm, children who met IMCI criteria in our study would have been categorized as 'HIV exposed/possible HIV'; for this category, the WHO IMCI manual recommends confirmation of HIV-1 infection status as soon as possible with the best available test, follow-up in 14 days, then monthly for 3 months and then every 3 months, or as per immunization schedule [4] . The delay from time of infection to presentation of IMCI clinical criteria indicates that reliance on these criteria alone will result in substantial delays before a health worker is prompted to recommend confirmatory testing and/or referral for early initiation of ART [8] . In settings in which receipt of virologic testing results may be delayed up to a period of weeks, or even months, the difference between time to diagnosis for IMCI compared with virologic testing will be smaller. Using either diagnostic tool, the delay to time of infection detection is particularly critical for infants with early HIV-1 acquisition (before 1 month of age), who demonstrate more rapid onset of morbidity and greater rates of mortality compared with infants with later acquisition [26] . The sensitivity observed in this study using two WHO criteria is somewhat lower than reported by Iliff et al. [12] for infants aged 6 (22 versus 44%) and 12 months (34 versus 57%); however, results are similar to a crosssectional study of IMCI performance among Kenyan infants (sensitivity of 20 and 26% for infants less than 6 and 6 to 12 months, respectively) [16] . The lower sensitivity and specificity reported here may be related to cohort differences or the retrospective rather than prospective classification of IMCI criteria; clinical assessments in prospective studies of IMCI performance may be more likely to identify IMCI criteria as clinical symptoms during a study visit. In this study, otitis and parotitis were not associated with HIV infection and their removal from the algorithm should be considered for this population.
Strengths of this study include the prospective, longitudinal cohort, its high power to discern time trends, and its unbiased assessment of IMCI clinical criteria. In this study, sensitivity estimates were undoubtedly reduced by high mortality in HIV-infected infants who were lost to follow-up or died before presenting with IMCI-specific symptoms at clinic visits. Diagnosis of persistent diarrhea relied on maternal recall, and could have led to some misclassification. Reporting of clinical illnesses may have been greater for infected infants, as health workers and mothers were sometimes aware of infant HIV status in real time, although the retrospective nature of our IMCI analysis means that clinicians and mothers were not preferentially biased toward looking for or reporting IMCI-specific signs or symptoms. This study relied on a 'snapshot' approach assessing clinical criteria available at discrete visits, because in our experience children are often seen by medical officers without access to their previous clinical records. For a provider or clinic with access to a child's medical history or past records, cumulative observation of IMCI criteria may improve algorithm performance. Differing HIV-1 prevalence, level of healthcare worker experience, duration of breastfeeding/HIV-1 exposure, and health status of infants should be considered when considering generalizability of this evaluation of IMCI performance [12] .
Although our data demonstrate IMCI performs poorly in this population, the feasibility and cost-effectiveness of infant HIV-1 testing must also be considered when considering early infant diagnosis in resource-limited settings [27] . Although virologic diagnosis is ideal, PCRbased testing is currently not achievable in many settings. Nucleic acid-based platforms that are affordable do not require instrumentation, and are available as a point-ofcare diagnostic test are urgently needed for infant HIV-1 diagnosis [28] , and would enable expansion of virologic diagnosis to many more sites.
In summary, although IMCI sensitivity increases with age, it is a poor diagnostic/screening test early in infancy when most infections occur and the need for diagnosis and initiation of ART is most urgent. Our findings underscore the critical need for expanded access to virologic-based rapid diagnostic technologies for infant HIV-1 infection in resource-limited settings. Despite its low sensitivity in infants, IMCI may still prove useful in identifying older children with undiagnosed HIV-1 infection, and children who acquire HIV-1 infection through late breast milk transmission.
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